Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical stage biopharmaceutical company that regularly issues news about its precision oncology pipeline and Generative Phosphoproteomics AP3 platform. Company announcements describe progress for its lead CHK1/CHK2 inhibitor ACR-368 in a registrational-intent Phase 2 or Phase 2b trial in endometrial cancer, as well as updates on ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1 development, and AP3-enabled preclinical programs such as the CDK11-targeting candidate ACR-6840.
News releases from Acrivon often cover interim clinical data, including response rates and tumor shrinkage in AP3-prioritized solid tumor types, details on dose-escalation cohorts, and observations of drug target engagement based on AP3 profiling. The company also reports on regulatory designations, such as FDA Fast Track status for ACR-368 monotherapy in endometrial cancer and FDA Breakthrough Device designation for the ACR-368 OncoSignature assay, as well as trial design elements like biomarker-selected and biomarker-unselected arms and combinations with ultra-low dose gemcitabine.
Investors and observers following ACRV news can expect updates on Acrivon’s presentations at scientific conferences, including AACR and AACR-NCI-EORTC, where the company highlights AP3-based mechanistic data, the AP3 KaiSR generative AI model, and pharmacodynamic insights for ACR-2316 and other candidates. The company also issues periodic financial results and business highlights, summarizing cash resources, research and development activities, and anticipated clinical and regulatory milestones for its AP3-enabled pipeline.
This ACRV news page aggregates these press releases and related coverage, providing a centralized view of Acrivon’s reported clinical progress, platform developments, and corporate updates over time.
Acrivon Therapeutics reported Q3 2024 financial results and business highlights. The company achieved a 62.5% confirmed overall response rate in their Phase 2b endometrial cancer study for ACR-368. The trial demonstrated statistical significance (p=0.009) in patient selection using their OncoSignature technology. The company completed enrollment for their first dose-escalation cohort in the Phase 1 study of ACR-2316. Financial position remains strong with $202.8 million in cash and equivalents, expected to fund operations into H2 2026. Q3 2024 net loss was $22.4 million, with R&D expenses of $18.9 million and G&A expenses of $6.3 million.
Acrivon Therapeutics (Nasdaq: ACRV) will present data on its AP3 platform at two scientific conferences: HUPO World Congress and EORTC-NCI-AACR Symposium. The presentations will showcase AP3's capabilities in drug discovery and clinical development.
Key highlights include:
- AP3-identified clinical biomarkers for ACR-368 led to a response-predictive OncoSignature assay, showing statistically significant prospective validation in an ongoing Phase 2b study.
- ACR-2316, a novel WEE1/PKMYT1 inhibitor, was optimized using AP3 to deliver superior single agent activity and complete tumor regression.
- AP3 enables overcoming challenges in biopharma, including biomarker discovery, resistance mechanism identification, and patient responder prediction.
The company will present posters on ACR-368 and ACR-2316 at both conferences, demonstrating AP3's impact on streamlined clinical development and drug design.
Acrivon Therapeutics (Nasdaq: ACRV), a clinical stage precision medicine company, announced the approval of equity awards under its 2023 Inducement Plan for certain employees. The awards, granted on October 15, 2024, consist of stock options to purchase a total of 61,950 shares of Acrivon common stock.
The stock options will vest according to the following schedule:
- 25% on the first anniversary of the first day of the month following each employee's effective employment date
- Additional 2.083% installments monthly thereafter
Vesting is subject to continued employment. The inducement grants were approved by Acrivon's Board of Directors in compliance with Nasdaq Rule 5635(c)(4) and serve as a material inducement to employment.
Acrivon Therapeutics (NASDAQ: ACRV) reported positive data from its ongoing Phase 2 trial of ACR-368 in endometrial cancer at ESMO. Key highlights include:
- 62.5% confirmed overall response rate in OncoSignature-positive patients
- Statistically significant segregation of responders (p-value = 0.009)
- Median duration of response not yet reached (~6 months at data cut-off)
- Endometrial cancer anticipated as first potential accelerated approval indication
Additionally, Acrivon announced FDA clearance of the IND for ACR-2316, with first-in-human dosing expected in Q4 2024. The company's AP3 Interactome platform is generating proprietary insights for drug development and patient selection.
Acrivon Therapeutics (Nasdaq: ACRV), a clinical stage precision medicine company, has announced its participation in the Cantor Global Healthcare Conference in New York. The company's president and CEO, Peter Blume-Jensen, M.D., Ph.D., will engage in a fireside chat on Tuesday, September 17, 2024, at 8:35 a.m. ET.
Acrivon utilizes its Acrivon Predictive Precision Proteomics (AP3) platform for drug candidate discovery and development, focusing on mechanistic matches to patients whose diseases are predicted to be sensitive to specific treatments. Interested parties can access a live webcast of the event through the company's investor relations website. A replay will be available shortly after the presentation.
Acrivon Therapeutics (Nasdaq: ACRV) announced a virtual investor event on September 14, 2024, to review positive Phase 2 clinical data of ACR-368 presented at ESMO and pipeline progress. The event will highlight:
1. Updated ACR-368 clinical data in endometrial cancer from the ongoing registrational intent Phase 2b study
2. Updates on lead assets ACR-368, ACR-2316, and the AP3 platform
3. Previous data showed a 50% confirmed response rate across ovarian and endometrial cancer patients
4. Enrollment for endometrial cancer patients is progressing ahead of schedule
5. The study represents the first potential approval opportunity for ACR-368
The ESMO poster presentation details and webcast information are provided in the announcement.
Acrivon Therapeutics (Nasdaq: ACRV) reported Q2 2024 financial results and business highlights. Key points include:
- Planned webcast in September 2024 during ESMO conference to update on clinical programs and AP3 platform progress
- Initial positive clinical data for ACR-368 showed 50% overall response rate in gynecological cancers
- On track to initiate Phase 1 study for ACR-2316 in Q4 2024
- Executed $130 million private placement financing
- Q2 2024 net loss of $18.8 million, compared to $13.9 million in Q2 2023
- Cash position of $220.4 million, expected to fund operations into second half of 2026
Acrivon Therapeutics, a clinical-stage biopharmaceutical company specializing in precision oncology, will present at the Jefferies Global Healthcare Conference on June 5, 2024. The company's CEO, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat at 9:30 a.m. ET. The event will be webcast live and accessible via the company's investor relations page. The presentation will utilize Acrivon's proprietary AP3 platform, which identifies patients whose tumors are likely to respond to specific oncology treatments. A replay of the webcast will be available for 30 days.
Acrivon Therapeutics reported its first quarter 2024 financial results and business highlights on May 14, 2024. The company, which leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform for developing precision oncology medicines, made significant strides in its clinical and preclinical pipeline.
Key achievements include the validation of the AP3 platform's ACR-368 OncoSignature assay, demonstrating a 50% overall confirmed response rate in patients with ovarian and endometrial cancer. The company has also accelerated the IND timeline for ACR-2316, a new WEE1/PKMYT1 inhibitor, with clinical trials expected to begin in Q4 2024. Financially, Acrivon reported a net loss of $16.5 million for Q1 2024, compared to $12.8 million in Q1 2023. The company raised $130 million in a private placement, extending its cash runway into H2 2026.
Summary not available.